Related Experiment Videos
Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for
M Nieborowska-Skórska1, M Nakashima, M Ratajczak
1Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, PA 19107.
Abstract:
Synthetic oligodeoxynucleotides (antisenses) complementary to bcr/abl breakpoint junction transcript on Philadelphia chromosome, or c-myb protooncogene inhibit partially the proliferation of Philadelphia positive leukemic cells (antisenses against bcr/abl and c-myb) and other tumor cells (antisenses against c-myb). This phenomenon is accompanied by specific downregulation of mRNA level of the particular gene. To develop a more effective procedure of tumor treatment the combination of low dose of cytostatic and bcr/abl or c-myb antisenses against Philadelphia chromosome positive cell line BV173, and the combination of anti-tumor cytotoxic T lymphocytes (CTL) and c-myb antisenses against melanoma cell line MM-28, were tested in vitro. Our results indicate that the combinations of conventional chemotherapeutic agent and antisense against bcr/abl or c-myb or tumor specific CTL and antisense against c-myb, are highly effective in killing of tumor cells and sparing normal cells. This creates the possibility to develop a more selective and effective treatment of neoplasia.
Insights
Antisense technology targeting bcr/abl and c-myb genes shows promise in cancer therapy. Combining antisense oligonucleotides with chemotherapy or T-cells effectively kills tumor cells while sparing normal cells.
Area of Science:
- Molecular Biology
- Oncology
- Gene Therapy
Background:
- Synthetic oligodeoxynucleotides (antisenses) can inhibit cancer cell proliferation.
- Targeting bcr/abl and c-myb genes shows potential for cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of combining antisense technology with conventional treatments for cancer.
- To investigate the potential of antisense against bcr/abl and c-myb in novel cancer therapies.
Main Methods:
- In vitro testing of antisense oligonucleotides against bcr/abl and c-myb in cancer cell lines.
- Combination therapy studies using cytostatics and anti-tumor cytotoxic T lymphocytes (CTL) with antisense agents.
Main Results:
- Antisenses against bcr/abl and c-myb partially inhibited proliferation of specific cancer cells.
- Combination of cytostatics/CTL with antisense agents demonstrated high efficacy in tumor cell killing.
- Normal cells were spared in combination therapy, indicating selectivity.
Conclusions:
- Antisense technology combined with conventional treatments offers a more selective and effective approach to cancer therapy.
- This strategy holds potential for developing novel treatments for neoplasia.